Narrative review suggests exercise rehabilitation may retard Cardiovascular-Kidney-Metabolic Syndrome progression
Review suggests exercise rehabilitation may slow progression of heart-kidney-metabolic syndrome
A narrative review of existing literature suggests exercise rehabilitation may retard Cardiovascular-Kidney-Metabolic Syndrome progression t…
Exercise rehabilitation may slow the progression of heart-kidney-metabolic syndrome by targeting multiple biological pathways to improve hea…
Retrospective study identifies five predictors for hypokalemia in STEMI patients
Can a simple checklist predict dangerous potassium drops after a major heart attack?
A retrospective observational cohort study of 320 STEMI patients at a single Chinese hospital identified five independent predictors for hyp…
A new checklist using five simple signs can predict dangerous potassium drops that trigger deadly heart rhythms after a major heart attack.
Autologous pericardial annuloplasty linked to lower TR recurrence in rheumatic heart disease
Study compares two surgical techniques for heart valve repair in rheumatic heart disease
A retrospective cohort study of 251 RHD patients undergoing tricuspid annuloplasty found that autologous pericardial soft-ring annuloplasty …
Using a patient's own tissue to repair a leaky heart valve in rheumatic disease kept the valve working better than artificial rings at four …
FDA Approves Xarelto (rivaroxaban) for multiple indications including stroke prevention in nonvalvular atrial fibrillation and treatment of VTE
FDA approves a new blood thinner called Xarelto for several heart and clot conditions
The FDA approved rivaroxaban (Xarelto), a factor Xa inhibitor, for multiple indications including reducing stroke risk in nonvalvular atrial…
FDA approves new blood thinner Xarelto to prevent dangerous clots in heart conditions, deep vein issues, and after major surgeries.
FDA Approves Xarelto (rivaroxaban) for Thromboprophylaxis in Pediatric Patients After Fontan Procedure
FDA approves Xarelto to help prevent blood clots in children with certain heart conditions
The FDA approved rivaroxaban (Xarelto) for thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who…
FDA approves Xarelto to prevent dangerous blood clots in children aged 2 and older born with heart defects who have had Fontan surgery.
Phase 4 study evaluates nitroglycerin's effects on stroke volume in 21 AHF patients
Can a common heart drug help people with acute heart failure breathe easier?
A Phase 4 study enrolled 21 patients with acute heart failure to evaluate the effects of nitroglycerin on stroke volume.
Nitroglycerin may help acute heart failure patients pump more blood and flush out fluid to ease breathing in the critical early hours of tre…
Stratified MINOCA Tx improves angina status at 12 months vs standard care in PROMISE trial
For heart attacks with clear arteries, does personalized treatment help? New trial shows it improves chest pain
In the PROMISE RCT (n=92), stratified treatment for MINOCA significantly improved angina status at 12 months vs standard care (mean SAQSS di…
Patients with heart attacks and clear arteries got better chest pain and quality of life after doctors found and treated the specific cause …
Phase 3 trial of milvexian for ACS prevention completes enrollment
Can a new drug help prevent heart attacks and strokes after a serious heart event?
The LIBERATE trial, a Phase 3 study, has completed enrollment of 14,194 participants with a recent acute coronary syndrome to evaluate if mi…
A new drug called milvexian is being tested to see if it lowers the risk of death, heart attack, or stroke after a serious heart event.
Phase 2a trial of DFV890 and MAS825 for inflammation in CHD/CHIP patients completes with 31 participants
Can two experimental drugs calm the dangerous inflammation linked to heart disease and a blood condition called CHIP?
A Phase 2a, multi-center, randomized, placebo-controlled, blinded study evaluated the efficacy, safety, and tolerability of DFV890 (oral dai…
A new trial tested two experimental drugs to safely turn down the dangerous inflammation driving heart disease in patients with CHIP.
Phase 2 trial tests pre-hospital glucocorticoid pulse in STEMI patients undergoing primary PCI
Phase 2 trial tests steroid pulse for heart attack patients before hospital arrival
A phase 2 randomized controlled trial enrolled 530 STEMI patients treated with primary PCI to test single-dose glucocorticoid pulse therapy …
A new trial tested giving a single steroid dose in ambulances before heart attack patients reach the hospital to reduce permanent heart dama…
Phase 2 pilot study evaluates ticagrelor monotherapy safety after stenting for acute MI
Can a single blood thinner prevent heart attacks after stent placement?
A single-center, single-arm, prospective phase II pilot study of 200 patients assessed the initial safety of ticagrelor monotherapy after co…
A new pilot study tests if one blood thinner alone can safely prevent heart attacks and stent clots after stent placement for heart attack p…
Colchicine reduces total plaque burden but not low attenuation plaque in stable CAD patients
Can a cheap anti-inflammatory drug slow heart disease? It might help reduce plaque buildup
In the EKSTROM RCT (n=84), low-dose colchicine (0.5 mg/day) did not significantly reduce low attenuation plaque volume (median change 0.1 vs…
A cheap anti-inflammatory drug called colchicine may help slow total plaque buildup in arteries for people already managing stable heart dis…